PE20061314A1 - Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo - Google Patents

Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo

Info

Publication number
PE20061314A1
PE20061314A1 PE2006000399A PE2006000399A PE20061314A1 PE 20061314 A1 PE20061314 A1 PE 20061314A1 PE 2006000399 A PE2006000399 A PE 2006000399A PE 2006000399 A PE2006000399 A PE 2006000399A PE 20061314 A1 PE20061314 A1 PE 20061314A1
Authority
PE
Peru
Prior art keywords
artemisinin
malaria
derivative
treatment
ferroquine
Prior art date
Application number
PE2006000399A
Other languages
English (en)
Inventor
Laurent Fraisse
Daniel Ter-Minassian
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20061314A1 publication Critical patent/PE20061314A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) FERROQUINA EN FORMA DE BASE LIBRE CARACTERIZADA POR UNA DOSIS DIARIA COMPRENDIDA ENTRE 50 Y 1600 mg; B) DERIVADO DE ARTEMISININA TAL COMO ARTESUNATO O ARTEMETER COMPRENDIDA EN UNA DOSIS DIARIA ENTRE 1-10 mg/Kg/DIA. DICHA COMPOSICION SE ADMINISTRA DURANTE UN PERIODO DE 2-4 DIAS CONSECUTIVOS Y ES DE ADMINISTRACION ORAL, RECTAL O INYECTABLE, SIENDO UTILES EN EL TRATAMIENTO DE PALUDISMO
PE2006000399A 2005-04-20 2006-04-17 Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo PE20061314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503932A FR2884715B1 (fr) 2005-04-20 2005-04-20 Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme

Publications (1)

Publication Number Publication Date
PE20061314A1 true PE20061314A1 (es) 2006-12-27

Family

ID=35385843

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006000399A PE20061314A1 (es) 2005-04-20 2006-04-17 Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
PE2010000537A PE20110119A1 (es) 2005-04-20 2006-04-17 Asociacion entre ferroquina y artesunato para el tratamiento del paludismo

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2010000537A PE20110119A1 (es) 2005-04-20 2006-04-17 Asociacion entre ferroquina y artesunato para el tratamiento del paludismo

Country Status (30)

Country Link
US (1) US20120258945A1 (es)
EP (1) EP1874293A1 (es)
JP (1) JP5148478B2 (es)
KR (1) KR20080009088A (es)
CN (2) CN101163470A (es)
AP (1) AP2782A (es)
AR (1) AR054253A1 (es)
AU (1) AU2006238506B2 (es)
BR (1) BRPI0610851A2 (es)
CA (1) CA2605385A1 (es)
CR (1) CR9425A (es)
DO (1) DOP2006000092A (es)
EA (1) EA012630B1 (es)
FR (1) FR2884715B1 (es)
GT (1) GT200600157A (es)
HN (1) HN2006015130A (es)
IL (1) IL186048A0 (es)
MA (1) MA29451B1 (es)
MX (1) MX2007012645A (es)
MY (1) MY145581A (es)
NO (1) NO20075920L (es)
NZ (1) NZ562117A (es)
PA (1) PA8669801A1 (es)
PE (2) PE20061314A1 (es)
SG (1) SG161270A1 (es)
TN (1) TNSN07359A1 (es)
TW (1) TWI387456B (es)
UA (1) UA96414C2 (es)
WO (1) WO2006111647A1 (es)
ZA (1) ZA200708800B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926993B1 (fr) * 2008-02-06 2011-03-11 Sanofi Aventis Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artemisinine ou l'un de ses derives pour le traitement du paludisme
FR2952823B1 (fr) * 2009-10-30 2012-04-20 Sanofi Aventis Utilisation de la ferroquine dans le traitement ou la prevention du paludisme
FR2951945B1 (fr) * 2009-11-05 2013-08-09 Sanofi Aventis Composition pharmaceutique
FR2961209B1 (fr) * 2010-06-11 2013-03-01 Sanofi Aventis Procede de synthese de la ferroquine par amination reductrice convergente.
FR2989588A1 (fr) * 2012-04-19 2013-10-25 Centre Nat Rech Scient Composes pour la prevention ou le traitement des infections par des virus de la famille des flaviviridae
JP6806563B2 (ja) 2013-11-08 2021-01-06 エクステラ・メディカル・コーポレーション 吸着媒体を使用する感染症の診断法
CN105250295B (zh) * 2014-07-07 2018-12-25 广州中医药大学科技产业园有限公司 一种联合用药物及其作为免疫调节剂的应用
WO2017015344A1 (en) * 2015-07-20 2017-01-26 University Of Vermont And State Agricultural College Use of cymanquine compounds as antimalarial agents
CN107802755A (zh) * 2017-11-08 2018-03-16 江西龙卿堂科技有限公司 一种具有防蚊防疟作用的青蒿软膏
KR102073961B1 (ko) * 2018-11-16 2020-02-05 (주)프론트바이오 메트포르민 및 페로센계 화합물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2022231238A1 (ko) * 2021-04-26 2022-11-03 심민보 아르테수네이트 또는 그의 염, 및 피로나리딘 또는 그의 염의 해열, 항염증, 항바이러스용, 또는 covid-19 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
CN113952360B (zh) * 2021-09-14 2023-03-10 上海交通大学 一种亚铁离子在治疗疟疾的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN166154B (es) * 1987-05-08 1990-03-24 Hoechst India
AP2006003557A0 (en) * 2003-09-04 2006-04-30 Cipla Ltd Antimalarial compositions and process thereof.

Also Published As

Publication number Publication date
FR2884715B1 (fr) 2007-06-15
WO2006111647A1 (fr) 2006-10-26
SG161270A1 (en) 2010-05-27
GT200600157A (es) 2006-11-07
EA200702282A1 (ru) 2008-02-28
FR2884715A1 (fr) 2006-10-27
HN2006015130A (es) 2010-08-19
JP2008536900A (ja) 2008-09-11
PE20110119A1 (es) 2011-03-08
ZA200708800B (en) 2009-01-28
NZ562117A (en) 2010-01-29
EA012630B1 (ru) 2009-10-30
TW200716092A (en) 2007-05-01
MA29451B1 (fr) 2008-05-02
TWI387456B (zh) 2013-03-01
AU2006238506A1 (en) 2006-10-26
CN102836163A (zh) 2012-12-26
EP1874293A1 (fr) 2008-01-09
CN101163470A (zh) 2008-04-16
AP2007004211A0 (en) 2007-10-31
TNSN07359A1 (en) 2008-12-31
PA8669801A1 (es) 2006-11-09
KR20080009088A (ko) 2008-01-24
NO20075920L (no) 2007-11-16
BRPI0610851A2 (pt) 2010-08-03
AP2782A (en) 2013-10-31
JP5148478B2 (ja) 2013-02-20
IL186048A0 (en) 2008-02-09
AR054253A1 (es) 2007-06-13
US20120258945A1 (en) 2012-10-11
CR9425A (es) 2008-02-20
UA96414C2 (ru) 2011-11-10
MX2007012645A (es) 2007-12-13
MY145581A (en) 2012-02-29
DOP2006000092A (es) 2006-11-15
CA2605385A1 (fr) 2006-10-26
AU2006238506B2 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
PE20061314A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
PA8591701A1 (es) Derivados de pirrolopirimidina
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
HN2001000037A (es) Derivados de eteres de pirazol como agentes antiinflamatorios/analgesicos
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
TW200626158A (en) Naphthaline derivatives
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
AR109263A2 (es) Composición que comprende moxidectina
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
UA97401C2 (ru) Экструдат с улучшенной маскировкой вкуса
DK2244703T3 (da) Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
PE20120956A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
CR10210A (es) Derivados de benzoisoindol para el tratamiento del dolor
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
CO5750041A1 (es) Metodo para la fabricacion de un medicamento a base de una mezcla de acidos grasos poliinsaturados para la prevencion de infecciones respiratorias en infantes
CR8172A (es) Saquinavir mesilato en forma de dosificacion farmaceutica oral
BRPI0513222A (pt) agente para promoção de recuperação de disfunção após o inicio de doença neurológica central

Legal Events

Date Code Title Description
FC Refusal